After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $29.51 and fluctuated between $29.91 as its day high and $28.27 as its day low. The current market capitalization of Insmed Inc is $4.22B. A total of 1.88 million shares were traded on the day, compared to an average of 1.67M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, INSM has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 29 BUYs and 31 SELLs from insiders. Insiders purchased 783,038 shares during that period but sold 182,885.
In the most recent transaction, Adsett Roger sold 5,251 shares of INSM for 28.63 per share on Jan 12. After the transaction, the Chief Operating Officer now owns 148,559 company shares. In a previous transaction on Jan 12, Flammer Martina M.D. sold 4,667 shares at 28.63 per share. INSM shares that Chief Medical Officer owns now total 106,898.
Among the insiders who sold shares, Adsett Roger disposed of 3,536 shares on Jan 10 at a per-share price of $28.90. This resulted in the Chief Operating Officer holding 153,810 shares of INSM after the transaction. In another insider transaction, Flammer Martina M.D. sold 1,245 shares at $28.90 per share on Jan 10. Company shares held by the Chief Medical Officer now total 111,565.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for INSM in the last 3 months, the mean price target is $42.50 with high estimates of $55.00 and low estimates of $35.00. In terms of 52-week highs and lows, INSM has a high of $32.00 and a low of $16.04.
As of this writing, INSM has an earnings estimate of -$1.15 per share for the current quarter. EPS was calculated based on a consensus of 12 estimates, with a high estimate of -$0.95 per share and a lower estimate of -$1.32. The company reported an EPS of -$1.78 in the last quarter, which was -57.50% lower than expectations of -$1.13.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. INSM’s latest balance sheet shows that the firm has $716.78M in Cash & Short Term Investments as of fiscal 2021. There were $612.27M in debt and $135.17M in liabilities at the time. Its Book Value Per Share was -$2.02, while its Total Shareholder’s Equity was $410.47M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for INSM is Buy with a score of 5.00.
